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Lazaroids have been reported to attenuate preser-
vation and reperfusion injury. In this study, we exam-
ined whether lazaroids can improve the outcome after 
48-hr canine liver preservation and transplantation. 
Adult female beagle dogs were randomized into 4 dos-
age groups (5 animals each). Lazaroid U-74389G was 
intravenously administered at a dose of 0 mg/kg, 6 
mg/kg, 10 mg/kg, or 15 mglkg to donors 30 min before 
harvesting and also to recipients 30 min before revas-
cularization. Control animals (0 mg/kg) were given the 
lazaroid vehicle. The liver grafts were orthotopically 
transplanted after 48 hr of hypothermic preservation 
in UW solution. Lazaroid treatment significantly im-
proved outcome after transplantation. Five-day ani-
mal survival increased from 0% in the control to 6M"o in 
the 6 mglkg group, 100% in the 10 mg/kg group, and 
80% in the 15 mglkg group. Lazaroid protected the 
hepatocytes from damage during preservation, and 
enhanced energy charge and hepatic blood flow after 
reperfusion. Histological alterations were signifi-
cantly less severe in the lazaroid-treated groups. The 
area of necrotic hepatocytes decreased from 43.7::t 17.7 
in the control to 13.5::t3.0 in the lazaroid 10 mg/kg 
group. These results indicate that lazaroid U-74389G 
has potential for improvement of clinical liver preser-
vation. 
Lazaroids are a group of new synthetic 21-aminosteroids, 
which inhibit iron-dependent lipid peroxidation without glu-
cocorticoid and mineralocorticoid actions (1). In addition to 
potent antioxidant properties, lazaroids have been shown to 
suppress cytokine production (2), adhesion molecule expres-
sion (3), and neutrophile activation and infiltration (4). From 
these unique biological features, lazaroids were first reported 
to ameliorate ischemia and reperfusion injury of the central 
nervous system (5-7). Later the effects of lazaroids were 
confinned in other tissues and organs in small and large 
animal experiments (8-15). 
In this study, we examined whether lazaroids can improve 
outcome after 48-hr liver preservation and orthotopic trans-
plantation in beagle dogs. Lazaroid U-74389G was selected 
from the lazaroid compounds and tested at three different 
doses. Animals receiving vehicle alone were used as the 
control. 
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MATERIALS AND METHODS 
Animals. Adult female beagle dogs, weighing 9 kg to 13 kg, were 
used as liver donors and recipients. After overnight fasting, the 
animals were anesthetized with thiopental-sodium (25 mglkg) for 
induction, and maintained with fluorane, nitrous oxide, and oxygen 
by positive pressure mechanical ventilation. Heart rate, arrythmia, 
arterial blood pressure, central venous pressure, and esophageal 
temperature were monitored during surgery. Blood gas and electro-
lytes were measured frequently and corrected if necessary. 
Operative procedures. Hepatic homograft procurement and ortho-
topic liver transplantation were performed using our standard lab-
oratory method (16, 17). In brief, the hepatic ligaments, the distal 
common bile duct, the portal vein, and the hepatic artery were 
dissected, and the liver was flushed with 1.5 L cold University of 
Wisconsin (UW) solution (ViaSpan, DuPont Merck Pharmaceutical 
Company, Wilmington, DE) via catheters inserted into the splenic 
vein (1 L) and the inferior abdominal aorta <0.5 L). The biliary tract 
was irrigated via cholecystostomy with 100 ml of normal saline. After 
removal, the graft was placed in a sterile plastic bag containing 0.5 
L ofUW solution, and kept at 4°C for 48 hr (until transplantation). 
The recipient liver was dissected and removed with the use of veno-
venous bypass during the anhepatic phase. The graft was revascu-
larized by end-to-end anastomoses of the suprahepatic vena cava, 
the infrahepatic vena cava, the portal trunk, and the abdominal 
aorta. Prior to completion of the infrahepatic vena cava anastomosis, 
the graft was perfused with 250 ml of cold lactated Ringer's solution 
through the portal vein to remove air and UW solution in the graft. 
The first 50 ml of effiuent from the flushing procedure was collected 
from the infrahepatic vena cava and stored at -70°C for later bio-
chemical analysis. After obtaining hemostasis, the transplant was 
completed by cholecystoduodenostomy for biliary reconstruction. 
Electrolyte solution (Plasmalyte, 1.5-2.0 L) and blood (limited to 
1500 mll collected from donor dogs were transfused to maintain 
recipient hemodynamics, Cephalosporin 1 g was given to animals 
intraoperatively and continued daily for 5 days. Animals were al-
lowed to eat and drink from the following morning. Oral cyclosporine 
20 mg/kg was administered daily for postoperative immunosuppres-
sion until the surviving animals were sacrificed at 14 days. 
Experimental groups. Lazaroid U-74389G was supplied by The 
Upjohn Co. (Kalamazoo, MI) and dissolved in a citrate buffer vehicle 
(pH 3.0) at a concentration of 1.5 mg/ml. The dissolved lazaroid was 
administered intravenously to donors 30 min before harvesting and 
to recipients 30 min before graft revascularization. Animals were 
randomized into four groups: lazaroid U-74389G at 0 mg/kg (Laz [0]), 
6 mg/kg (Laz [6]), 10 mg/kg (Laz [lOll, or 15 mg/kg (Laz [15]). The 6 
mglkg dose was the dose that The Upjohn Company recommended. 
Control animals (Laz [O])were given the same amount of vehicle as 
the Laz 10 group, 
Assessments. Liver enzyme levels. including glutamic oxaloacetic 
transaminase (GOT), glutamic pyruvic transaminase (GPTJ, and 
lactate dehydrogenase (LDH), from the effiuent of the final flushing 
solution and from postoperatively collected blood samples were mea-
sured using a Technicon RA500 autoanalyzer <Bayer, Tarrytown. 
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NY>. Wedge biopsy samples of liver tissues were collected before 
graft procurement, at the end of the 48-hr preservation period, and 1 
hr after graft reperfusion. The biopsy specimens were halved: one 
section was immediately frozen in liquid nitrogen for biochemical 
analysis and the other was fixed in buffered formalin for histopatho-
logic study. 
Liver tissues taken for biochemical analysis were analyzed for 
protein concentration, adenine nucleotides, purine catabolites, ma-
londialdehyde, and myeloperoxidase. Protein concentration of the 
homogenate was measured using the Bio-Rad protein assay kit <Bio-
Rad, Richmond, CAl method described by Bradford et al. (18). Ade-
nine nucleotides (AN) and purine catabolites (PC) were measured 
using a Waters HPLC system (19) (Waters Chromatography Divi-
sionIMillipore Corp., Milford, MA; Model 510 pumps, Model 484 
absorbance module, and Model 717 WISP system). Concentrations of 
AN and PC were monitored at 254 nm (Waters 484, Tunable Absor-
bance Detector). Energy charge (EC) was calculated using the equa-
tion (ATP + [112} ADP/(ATP + ADP +AMP) (20). Malondialdehyde 
(MDA) concentration was estimated by thiobarbituric acid reaction 
by fluorospectrophotometry (21) (excitation wavelength 515 nm; 
emission wavelength 553 nm; Shimadzu fluorospectrophotometer, 
Model RF5000U, Shimadzu Corp., Kyoto, Japan). Myeloperoxidase 
(MPO) activity assay was measured using the fluorospectrophoto-
metric method of Krawisz et al. (22). One unit of MPO activity was 
defined as the concentration that caused a 1.0 change in optical 
density at 460 nm for 1 min at 22°C. 
Liver sections taken for histopathology were stained by hematox-
ylin and eosin and examined by a single pathologist without knowing 
the groups and the timing of tissue sampling. In addition, the area of 
necrotic hepatocytes was quantified by a morphometric method us-
ing an eyepiece with 135 intersections. Morphometry was performed 
on five randomly selected periportal fields per section at a magnifi-
cation of 400X. 
Measurement of hepatic blood flow was performed before liver 
harvesting and one hr after graft reperfusion using an ultrasonic 
Doppler flowmeter (Transonic T201D, Transonic Systems Inc., 
Ithaca, NY> and a laser Doppler flowmeter (Transonic ALF21). Flow 
values for both machines were expressed as mlIminll00 g liver tissue. 
Statistics. Values are expressed as the mean :!: SD. Analysis of 
variance between groups was performed using the Kruskal-Wallis H 
test. When the analysis of variance showed a significant difference 
(P<0.05), the Mann-Whitney U test was used to determine the P 
values between each group. Animal survival was determined using 
the Kaplan-Meier method, and the log-rank test was used to deter-
mine significance. 
RESULTS 
Clinical observations. Intravenous administration of 
U-74389G or vehicle alone caused no important hemody-
namic changes in either donors or recipients. There was mild 
but transient acidosis after infusion in all animals. Cold 
ischemia time (49.2:t 1.2 hrl, warm ischemia time (53:t 13 
min), and graft weight loss during cold storage (15.3:t6.8%), 
were not statistically significantly different in the experi-
mental groups. 
Survival. Lazaroid U-74389G significantly improved ani-
mal survival and reduced the incidence of graft failure during 
the early postoperative·period (Fig. 1). While all animals in 
the Laz 0 group died of graft failure. only 2 animals in the 
Laz 6 group and no animals in the Laz 10 or Laz 15 group 
died of graft failure one day after transplantation. Animals 
dying of graft failure had pulmonary edema and various 
amounts of serosanguinous ascites at autopsy. One Laz 15 
animal died of intussusception on postoperative day 3. Five-
day animal survival was 0':0 in the Laz 0 group. 60'7" in the 
Laz 6 group. lOOlk in the Laz 10 grouP. and 80"{- in the Laz 
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FIGURE 1. Animal survival after liver transplantation. The Laz 0 
group was inferior to the Laz 6 group (P<6.03l, the Laz 10 group 
(P<O.Ol), and the Laz 15 group (P<O.Ol). Treated groups were not 
statistically significantly different. 
15 group. However, after 5 days only 4 animals (1 in the Laz 
10 and 3 in the Laz 15 group) survived for 14 days. The 
remaining 8 animals were lost to vascular thrombosis (n=3), 
cholangitis (n=2), intussusception (n=I), peritonitis (n=I), 
or bleeding duodenal ulcer (n=I). The difference in animal 
survival in the treated groups was not statistically signifi-
cant. 
Liver enzyme release. Liver enzymes (GOT, GPT, LDH) 
released into the effluent after final flushing were signifi-
cantly lower in the Laz 10 group than the other three groups 
(Fig. 2). Similarly, LDH blood levels 1 hr after reperfusion 
were lower in animals receiving higher doses of U-74389G, 
but the difference was not significant. Liver enzymes of the 
surviving animals did not return to normal 14 days after 
transplantation. 
Biochemistry. At higher doses (Laz 10 and Laz 15), lazaroid 
U-74389G retarded the degradation of adenine nucleotides to 
purine catabolites during preservation, and enhanced energy 
resynthesis after graft revascularization (Table 1). Cold stor-
age induced a universal decline in adenine nucleotides and a 
corresponding increase in purine catabolites in all groups. 
The tissue concentration of total adenine nuc1eotides was 
significantly higher in the Laz 10 group than the Laz 0 group, 
and the tissue concentration of total purine catabolites was 
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significantly lower in the Laz 15 group than the Laz 0 group. 
At 1 hr after reperfusion the energy charge of Laz 10 livers 
returned to normal levels, while the energy charge of the 
other 3 groups was significantly below normal. Although 
lazaroid U-74389G has been known to inhibit lipid peroxida-
tion, MDA levels at the end of preservation and at 1 hr after 
reperfusion showed no significant difference among the 
groups. Levels increased equally during preservation and 
declined to below normal after reperfusion. Although MPO 
levels were undetectable after the neutrophils were washed 
from the liver by the preservation solution, they rose signif-
icantly, and they were higher than normal after reperfusion. 
Neutrophil accumulation in livers given vehicle alone was 
double that of the Laz 15 group animals. 
Hepatic blood flow. Upon portal unclamping, heteroge-
neous reperfusion and the occurrence of outflow block were 
always seen in livers treated by vehicle alone. Lazaroid 
U-74389G ameliorated these disturbances and improved he-
patic blood flow, particularly at the higher doses (Fig. 3). 
Portal blood flow, hepatic arterial blood flow, and hepatic 
tissue blood flow of normal livers were measured at 186:!:80 
mllminll00 g liver, 53:!:24 mlIminJ100 g liver, and 13:!:2 
mlIminJI00 g liver, respectively. At 1 hr after reperfusion, 
these three estimates in Laz 0 and Laz 6 livers decreased to 
one-third of the normal values, whereas both hepatic arterial 
blood flow and hepatic tissue flow in Laz 10 and Laz 15 
groups were significantly higher than those of the other two 
groups. 
Histopathology. No morphological difference could be de-
tected between the groups prior to revascularization. After 
reperfusion, livers from the animals receiving no treatment 
(Laz 0 group) showed severe structural abnormalities, such 
as diffuse hepatocyte necrosis, disarray of hepatocyte cords, 
disaggregation of hepatocytes, and hepatic congestion (Fig. 
4A). In contrast, the treated livers, particularly from the Laz 
10 group animals, had rather well-preserved hepatic archi-
tecture with small foci of the necrotic area and/or single-cell 
necrosis (Fig. 4B). The necrotic hepatocyte area was mea-
sured at 43.7:!:17.7% in the Laz 0 group, 16.8:!:6.3% in the 
Laz 6 group, 13.5:!:3.0% in the Laz 10 group, and 31.5:!:5.7% 
in the Laz 15 group (Fig. 5l. The necrotic area of Laz 6 and 
Laz 10 was significantly less than the other two groups. 
DISCUSSION 
This study demonstrated that lazaroid U-74389G signifi-
cantly improved the outcome of beagle dogs after 48-hr liver 
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FIGURE 4. (A) Control group (C4) liver 48 hr after preservation with 
UW solution; treatment with citrate buffer. The liver parenchyma 
showed significant necrotic damage that occupied more than 50% of 
hepatic tissue. There was loss of hepatic plate structure and disin-
tegration of hepatocytes. (H&E; x lOO.(S) Experimental group (No. 
lOR) liver 48 hr after preservation with UW solution and treatment 
with lazaroid 10 mg/kg of the donor and recipient. The liver paren-
chyma showed small foci of necrotic damage that occupied 10-15% of 
hepatic tissue. (H&E; x 100). 
preservation and transplantation. Lazaroid U-74389G not 
only ameliorated hepatocyte damage during hypothermic 
storage, but also attenuated reperfusion injury after graft 
revascularization. Restoration of energy charge and hepatic 
blood flow were greatly enhanced by lazaroid treatment. 
Donor and recipient treatment with lazaroid U-74389G pre-
vented graft failure and significantly improved animal sur-
vival. Of the three doses studied in this experiment, 10 mg/kg 
of lazaroid U-74389G was found to be the most effective. 
The poor outcome of the Laz 0 group is consistent with 
previous studies of 48-hr liver preservation in our laboratory 
(23,24), While UW solution has proven to be superior to other 
preservation solutions (25, 26), we have not been able to 
effectively preserve the canine liver for 48 hr. In contrast to 
the flawless results after 24-hr liver preservation, grafts 
preserved for 48 hr consistently failed, showing extensive 
damage to the hepatocytes and microvasculature (23). How-
ever, these results are contrary to other reports (27, 28), 
which showed consistently better results with 48-hr canine 
liver preservation. The discordant results may be attribut-
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Laz 0 and Laz 15 groups. 
able to differences in the experimental model. Other investi-
gators used larger mongrel dogs and laboratory-made fresh 
UW solution, and pretreated the liver donors with phentol-
amine or chloropromazine and hydrocortisone. In our labo-
ratory, we attempt to mimic clinical practice by using com-
mercially available UW solution and by not pretreating the 
donor. Of factors that differ in the two models, the use of 
laboratory-made fresh UW solution appears to be the most 
important. Reduced glutathione (GSH) in UW solution spon-
taneously converts to its oxidized form (aSSa) over time, 
which causes it to become less effective for prolonged liver 
preservation (29). This suggests that antioxidants are crucial 
for preservation of hepatic homografts. 
Liver damage from ischemia and reperfusion has largely 
been explained by the generation of superoxide radicals 
(30,31). Superoxide anions and hydrogen peroxides are pro-
duced by the xanthine oxydase enzyme system via the con-
version of hypoxanthine to xanthine. Highly toxic hydroxyl 
radicals are generated in the presence of ferrous iron (Fe++) 
via the Harber-Weiss reaction or Fenton reduction. Other 
superoxide anion species are produced by the NADPH-depen-
dent oxydase system. These superoxide radicals interact with 
lipids, proteins, nucleic acids, and cell membranes, and cause 
lipid peroxidation in hepatocytes, endothelial cells, Kupffer 
cells, and infiltrating inflammatory cells. Lipid peroxides, in 
tum, impair cellular and subcellular function, and often lead 
to cell death. Lipid peroxides also stimulate cytokine produc-
tion, mediate arachidonic acid metabolism, induce expression 
of adhesion molecules, and activate leukocyte adherence and 
infiltration. Although cells are equipped with defensive en-
dogenous antioxidants, supplemental exogenous antioxi-
dants are needed to protect cells from increased free radical 
generation (32). 
Lazaroids are a novel form of antioxidant that inhibits 
iron-dependent lipid peroxidation. and they were developed 
in studies of the effect of large doses of methylpredonisolone 
on central nervous ischemia. Compared with a large dose of 
methylpredonisolone, lazaroids were reported to be 10,000 
times more potent in inhibiting lipid peroxidation (11. Al-
though the mechanism of action is still unclear, attenuation 
of ischemia and reperfusion injury by lazaroid was found in 
the central nervous system of rats (5, 6) and dogs (7), and 
later in patlents (331. The protective etTect was subsequently 
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confirmed in the heart (8, 9), lung (10), kidney (14, 15), and 
intestine (13) after ischemia (warm and cold) and reperfu-
sion. Recent reports have shown that lazaroid compounds 
maintain endothelial cell viability in a dose-dependent man-
ner (II, 12). Pretreatment of the donor with lazaroid reduced 
liver enzyme release and phospholipase ~ release after 
24-hr preservation in an ex vivo isolated pig liver perfusion 
model (12). They also showed that lazaroid pretreatment of 
rats receiving 24-hr-preserved livers allowed survival to in-
crease from 30% without treatment to 90% with treatment. 
These results, except for changes in MDA, are consistent 
with the findings obtained in our study. Cosenza et al. found 
that postreperfusion MDA increased in only vehicle-treated 
livers, while our study showed that MDA increased in all 
experimental groups during preservation and decreased to 
below normal after reperfusion. Ferguson et al. (34) reported 
MDA changes in rat livers that were similar to our results. A 
more specific and sensitive analytical method is required to 
elucidate these differences, since the measurement of MDA 
to estimate lipid peroxidation is rather crude. 
In conclusion, lazaroids are effective for prolonging the 
preservation period of hepatic homografts, with a potential 
for clinical use. However, before embarking on a clinical trial, 
several issues need to be considered. First, despite successful 
48-hr canine liver preservation, the agent appears to be use-
ful for improving graft viability within the current preserva-
tion time frame (35). It is apparent from the present study 
that the longer the preservation time, the greater the inci-
dence of vascular and biliary complications. Second, it should 
be determined whether lazaroid treatment is needed for both 
donor and recipient, and when the drug should be adminis-
tered. Third, it is especially important to determine the 
proper clinical dose, since lazaroids have aU-shaped dose-
response curve (33) and have different pharmacokinetics be-
tween male and female (36). This last question is currently 
under investigation in multicenter trials with central ner-
vous injuries. 
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THE EFFECT OF LAZAROID (U74500A), A NOVEL INHIBITOR OF 
LIPID PEROXIDATION, ON 24·HOUR HEART PRESERVATION 
A STUDY BASED ON A WORKING MODEL USING CROSS-CIRCULATED BLOOD-PERFUSED RABBIT HEARTSl 
TAKAHIRO NISHIDA, SHIGEKI MORITA,2 KAzmruKI MIYAMOTO, MUNETAKA MASUDA, RYUJI TOMINAGA, 
YOSHITO KAWACHI, AND HrSATAKA YASUI 
Department of Cardiovascular Surgery, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan 
Lazaroid, an inhibitor of iron-mediated lipid peron-
dation, has been shown to reduce free radical-medi-
ated injury after ischemia and reperfusion. We thus 
examined the efficacy of pretreatment with lazaroid 
(U74500A) in enhancing functional recovery after 
24·hr heart preservation. An isolated rabbit heart 
model perfused with the blood from a support rabbit 
was used. Before preservation, either U74500A (4 mg/ 
kg, group L; n=6) or solvent (group Sj n=7) was given 
to the donor rabbit. After 24-hr preservation with UW 
solution at O°C, all hearts were perfused with cross-
circulated blood for 60 min with the Langendorffmode 
followed by 40 min of the working mode. In group S, 
ventricular fibrillation (VO after reperfusion was ob-
served in all hearts, whereas no Vfwas observed in the 
U74500A-pretreated group. In group L, the serum cre-
atine phosphokinase; its isozyme, troponin-Tj and se-
rum lipid peroxide levels after 10 min of reperfusion 
were all significantly (P<0.05) lower than those in 
group S. The Frank-Starling curve (indicating the left 
atrial pressure-aortic flow relationship) showed a sig-
nificant left and upward shift in group L compared 
with that in group S (P<O.OOOI). The heart pretreated 
with U74500A showed less ischemia.reperfusion in-
jury, better ventricular function, and a lower lipid 
peroxide level. We thus conclude that the inhibition of 
I Presented at the 21st Annual Meeting of the American Society of 
Transplant Surgeons. May 17-19. 1995. Chicago. IL. 
" Address correspondence to Shigeki Morita. M.D .. Department of 
Cardiovascular Surgery. Facultv of Medicine. Kvushu University. 
:1-1-1 ~faidashiK Higashi-ku. Fukuoka rl12. Japan. 
lipid peroxidation with lazaroid appears to offer some 
potential benefits for long·term heart preservation. 
Reactive oxygen species such as the superoxide anion and 
hydroxyl radical are thought to play an important role in 
ischemia-reperfusion injury (1-2). Several studies have at-
tempted to reduce myocardial injury using such antioxidants 
as superoxide dismutase, catalase, and allopurinol (1-6). A 
failure to neutralize the reactive oxygen species results in the 
initiation of lipid peroxidation (2), which thus causes cell 
membrane injury. 
U74500A is one of the 21-aminosteroids (lazaroids) without 
glucocorticoid and mineralcorticoid side effects and strongly 
inhibits lipid peroxidation by chelating iron (7-8). Although 
several reports have demonstrated the effect of lazaroids on 
ischemia-reperfusion injury of the central nerve system (9), 
kidney (10), liver (11), lung U2-13), and heart (14-17), the 
cardioprotective effect on prolonged hypothermic cardiac 
ischemia has not yet been investigated. 
In this study, we examined the cardioprotective effect of 
this agent after 24-hr preservation. An isolated rabbit heart 
perfused with cross-circulated blood was used for the func-
tional evaluation. We also measured the serum lipid peroxide 
(LPOl* level to elucidate the effect of this drug. 
, Abbreviations: AoF. aortIc flow rate: CBF. coronary blood flow 
rate: CK. creatine phosphokinase: CK-MB. creatine phosphoki-
nase-MB isozyme: LAP. left atrial pressure: LPO. lipid peroXIde: 
:o.rv02. myocardial oxvgen consumption: TnT. troponin-T: Vf. ven-
tricular fibrillatIOn: LTW. UnIversltv of WisconSIn. 
